BETA: Please send your feedback!

Intercept Pharmaceuticals

NAS:ICPT

Pharmaceuticals: Other

$2.69bn
SMALL cap
$91.23 (0.77%)
-6.91%
since start of 2019
  • 1
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 1
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5

About

Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
website

Headquarters

10 Hudson Yards
37th floor
New York, NY 10001

Executives

Name Title Gender
David A. Shapiro, MD Chief Medical Officer & Executive VP-Development Male
Mark E. Pruzanski, MD President, Chief Executive Officer & Director Male
Paolo Fundar˜ Chairman Male
Roberto Pellicciari, PhD Founder Male
Mark J. Vignola, PhD Director-Investor Relations Male
Sandip S. Kapadia, MBA, CPA Chief Financial Officer Male
Jerome B. Durso Chief Operating Officer Male

Mindful Investing Summary

  • 1
  • 2
  • 3
  • 4
  • 5
  • Carbon Footprint N/A
  • Pollution Prevention N/A
  • Water Conservation N/A
  • Data & Privacy Protection N/A
  • Consumer Health, Wellness & Safety N/A
  • Employee Ownership, Satisfaction, Benefits & Pay N/A
  • Workplace Health and Safety N/A
  • Integrity of Corporate Governance N/A
  • Ethical Practices N/A
  • Usage of Conflict Materials N/A
  • Forced Labor N/A
  • Diversity of Corporate Leadership 1

Intercept Pharmaceuticals - Competitors and Related Companies

How Intercept Pharmaceuticals stacks up to its peers in the Pharmaceuticals: Other industry or with competing business segments.

Intercept Pharmaceuticals

NAS:ICPT

Pharmaceuticals: Other

$2.69bn
SMALL cap
$91.23 (0.77%)
-6.91%
since start of 2019
  • 1
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 1
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5
Loading…